the aid library

Sort by:

Direction:

European Drug Report 2019: trends and developments.

European Monitoring Centre for Drugs and Drug Addiction European Union (2019) C1

The Trends and Developments report presents a top-level overview of the drug phenomenon in Europe, covering drug supply, use and public health problems as well as drug policy and responses. Together with the online Statistical Bulletin and 30 Country Drug Reports, it makes up the 2019 European Drug ... more

Download (867)

View PDF (1052)

Towards Access 2030. WHO Medicines and Health Products Programme Strategic Framework 2016-2030

(2017) C_WHO

Download (207)

View PDF (278)

European Drug Report - Trends and Developments

European Monitoring Centre for Drugs and Drug Addiction (2018) C1

Table of contents: - Preface - Introductory note and acknowledgements - Commentary - Chapter 1: Drug supply and the market - Chapter 2: Drug use prevalence and trends - Chapter 3: Drug-related harms and responses - Annex: National data tables Available in 24 languages on: http://www.emcdd... more

Download (200)

View PDF (281)

Roadmap for introduction and roll‐out of Merck rVSV‐ZEBOV Ebola Virus Disease vaccine in African countries

World Health Organization WHO (2019) C_WHO

Revised working paper following AVAREF meeting February 2019. WHO has published a roadmap aiming to coordinate partners’ actions and contributions to the licensing and roll-out of Merck’s Ebola vaccine (VSV-ZEBOV) in African countries. The vaccine was developed during the West Africa Ebola epi... more

Download (509)

View PDF (783)

Access to medicine Index 2022

Access to Medicine Foundation (2022) C2

Globally each year, millions of people suffer illness or lose their lives because the vaccines, medicines and diagnostic tests that they need are either unavailable or unaffordable – and this lack of access to medicine is acute in low- and middle-in- come countries (LMICs). While the COVID-19 pan... more

Download (1190)

View PDF (1328)

Medicinal products under development for the treatment of Ebola

European Medicines Agency EMA (2014)

Interim Assessement Report The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment of people infecte... more

Download (316)

View PDF (523)

Guidelines on second-and third-line medicines and type of insulin for the control of blood glucose levels in non-pregnant adults with diabetes mellitus

World Health Organization WHO (2018) C_WHO

The new guidelines provide public health guidance on pharmacological agents for managing hyperglycaemia in type 1 and type 2 diabetes for use in primary health-care in low-resource settings. These guidelines update the recommendations for managing hyperglycaemia in the WHO Package of Essential NCD I... more

Download (86)

View PDF (113)

Tripartite meeting held between the PMDA, EMA, and FDA in Kyoto, Japan to discuss convergence on approaches for the evaluation of antibacterial drugs

European Medicines Agency (2017) C2

Meeting summary

Download (136)

View PDF (157)

Guideline on the assessment of the risk to public health from antimicrobial resistance due to the use of an antimicrobial veterinary medicinal product in food producing animals

EMA European Medicines Agency (2018) C2

This guideline provides advice in regards to applications for Marketing Authorisations for antimicrobial veterinary medicinal products (VMPs) on the data required and the methodology to be used for performing an assessment of the risk to public health from antimicrobial resistance (AMR) due to use o... more

Download (102)

View PDF (145)

ECDC/EFSA/EMA second joint report on the integratedanalysis of the consumption of antimicrobial agents andoccurrence of antimicrobial resistance in bacteria fromhumans and food-producing animals

European Centre for Disease Prevention and Control (ECDC), European Food Safety Authority (EFSA) andEuropean Medicines Agency (EMA) (2017) C_CDC

The second ECDC/EFSA/EMA joint report on the integrated analysis of antimicrobial consumption (AMC) and antimicrobial resistance (AMR) in bacteria from humans and food-producing animals addressed data obtained by the Agencies’ EU-wide surveillance networks for 2013–2015. AMC in both sectors, exp... more

Download (95)

View PDF (145)

Manejo clínico del COVID-19: tratamiento médico - Documento técnico

Centro de Coordinación de Alertasy Emergencias Sanitarias Ministerio de sanidad - España (2020) C1

La Agencia Española de Medicamentos y Producto Sanitarios (AEMPS) está monitorizando de manera continua con los expertos de las agencias europeas, la EMA y el resto de agencias mundiales todos los datos relativos al uso de medicamentos para tratar la COVID-19. Se trata de... more

Download (106)

View PDF (137)

ECDC/EFSA/EMA first joint report on the integrated analysis of the consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals

European Centers for Disease Control and Prevention ECDC (2015) C2

The ECDC, the EFSA and the EMA have for the first time jointly explored associations between consumption of antimicrobials in humans and food-producing animals, and antimicrobial resistance in bacteria from humans and food-producing animals, using 2011 and 2012 data currently available from their re... more

Download (84)

View PDF (126)

COVID-19: reminder of risk of serious side effects with chloroquine and hydroxychloroquine

European Medicine Agency (2020) CC

23 April 2020EMA/202483/2020 Rev Chloroquine and hydroxychloroquine are known to potentially cause heart rhythm problems, and these could be exacerbated if treatment is combined with other medicines, such as the antibiotic azithromycin, that have similar effects on the heart.